Evidence map›Paper›PMID 41549795›Full record

ArticleClinical pharmacology in drug development2026

A Phase 1 Dose-Escalation, Food Effect, and Drug-Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR-1505, in Healthy Volunteers.

Vipul K Gupta, Brian Yoo, Daniel Weiss, Frank G Basile, Edgar Schuck, Christopher M Rubino, Sen Zhang, Stephen E Maxwell, Wenxin Zheng, Joanne B L Tan and 7 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology in drug development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Vipul K GuptaSchrödinger Inc., New York, USA.
Brian YooSchrödinger Inc., New York, USA.
Daniel WeissSchrödinger Inc., New York, USA.
Frank G BasileSchrödinger Inc., New York, USA.
Edgar SchuckSchrödinger Inc., New York, USA.
Christopher M RubinoInstitute for Clinical Pharmacodynamics, Schenectady, NY, USA.
Sen ZhangSchrödinger Inc., New York, USA.
Stephen E MaxwellSchrödinger Inc., New York, USA.
Wenxin ZhengSchrödinger Inc., New York, USA.
Joanne B L TanParvus Therapeutics, South San Francisco, CA, USA.
David StenehjemUniversity of Minnesota, College of Pharmacy, Duluth, MN, USA.
Paul B WatkinsEshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Margaret DuganSchrödinger Inc., New York, USA.
Wu YinSchrödinger Inc., New York, USA.
D Hamish WrightSchrödinger Inc., New York, USA.
Karen AkinsanyaSchrödinger Inc., New York, USA.
Jason LickliterNucleus Network Ltd., Melbourne, VIC, Australia.

Funding

Schrödinger
6 · The paper itself

Abstract

SGR-1505 is a novel small-molecule inhibitor of MALT1, a key mediator of NF-κB signaling implicated in the pathogenesis of B-cell malignancies. This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of SGR-1505 in healthy volunteers. In this four-part, open-label study, 73 participants received single or multiple oral doses of SGR-1505 (25-225 mg). A food effect study assessed SGR-1505 exposure with and without a high-calorie, high-fat meal. The CYP3A4 drug-drug interaction potential of SGR-1505 was evaluated by co-administration with posaconazole, a strong CYP3A4 inhibitor. SGR-1505 was rapidly absorbed (median T

Indexed as

Food-Drug InteractionsMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinAdministration, OralAdolescentAdultArea Under CurveCytochrome P-450 CYP3A InhibitorsDose-Response Relationship, DrugDrug InteractionsFemaleHealthy VolunteersHumansMaleMiddle AgedTriazolesYoung AdultCytochrome P-450 CYP3A InhibitorsMALT1 protein, humanMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinposaconazoleTriazoleshealthy volunteersMALT1pharmacodynamicspharmacokineticsPhase 1SGR‐1505

Identifiers

PMID41549795
PMCPMC12813652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.